AC Immune ((ACIU)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: AC Immune is conducting a Phase 1 clinical study titled [18F]ACI-15916 PET in α-synucleinopathies to evaluate a new PET tracer, [18F]ACI-15916, for imaging α-synuclein deposits in the brain. This study aims to determine the safety and effectiveness of this tracer in detecting α-synuclein, a protein linked to diseases like Parkinson’s, Lewy body dementia, and Multiple System Atrophy, compared to healthy individuals.
Intervention/Treatment: The intervention being tested is [18F]ACI-15916, a radioactive imaging agent administered intravenously. It is designed to help visualize α-synuclein deposits in the brain through PET scans.
Study Design: This interventional study is non-randomized with a parallel assignment model. It is open-label, meaning there is no masking, and its primary purpose is diagnostic. Participants include those with suspected α-synucleinopathies and healthy volunteers.
Study Timeline: The study began on March 18, 2025, with the latest update submitted on April 8, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
Market Implications: The progress of this study could significantly impact AC Immune’s stock performance, as successful results may enhance their market position in neurodegenerative disease diagnostics. Investors should watch for updates, as positive outcomes could influence competitive dynamics within the industry.
The study is currently recruiting, with further details available on the ClinicalTrials portal.